Analysis of U.S. Patent 9,539,241: Scope, Claims, and Landscape
U.S. Patent 9,539,241, titled "Novel pharmaceutical compositions containing bisphosphonates," issued on January 10, 2017, to B. Braun Melsungen AG. The patent covers specific pharmaceutical compositions designed to improve the stability and efficacy of bisphosphonates, a class of drugs commonly used to treat bone diseases like osteoporosis. The claims define the precise chemical and physical characteristics of these compositions, including the concentration of bisphosphonate, the presence of specific stabilizers, and the pH range. The patent landscape reveals active research and development in bisphosphonate formulations, with several other patents addressing similar areas, highlighting a competitive but fertile ground for innovation in bone disease therapeutics.
What Is the Core Technology Protected by U.S. Patent 9,539,241?
The patent protects novel pharmaceutical compositions containing bisphosphonates. These compositions are formulated to enhance the stability of bisphosphonate drugs, which are susceptible to degradation, particularly in aqueous solutions. The invention addresses issues such as precipitation, aggregation, and loss of potency over time.
The core technology involves the stabilization of bisphosphonate molecules through specific excipients and controlled pH. Bisphosphonates, characterized by a P-C-P backbone, are potent inhibitors of osteoclast-mediated bone resorption. However, their chemical nature can lead to instability in liquid formulations.
The patent defines these compositions by specific parameters:
- Bisphosphonate Concentration: The claims specify a range for the bisphosphonate active pharmaceutical ingredient. For example, claim 1 defines a composition containing a bisphosphonate in an amount from 0.01% to 5% by weight.
- Stabilizing Agents: The compositions include specific stabilizing agents. These agents are critical for preventing degradation and maintaining the integrity of the bisphosphonate. Examples cited include amino acids, chelating agents, and buffering agents.
- Amino Acids: Claim 1 specifies the inclusion of an amino acid, such as glycine, alanine, or lysine, in an amount from 0.01% to 10% by weight.
- Chelating Agents: The patent also covers the use of chelating agents. An example provided is EDTA (ethylenediaminetetraacetic acid), which can complex metal ions that might catalyze bisphosphonate degradation.
- pH Control: The pH of the composition is a crucial parameter. The patent claims compositions with a pH in a specific range, typically between 3.5 and 7.0, to optimize bisphosphonate stability and solubility.
- Solvent System: The compositions are typically aqueous solutions. The patent specifies water as the solvent.
The underlying problem addressed is the inherent instability of bisphosphonates in solution, which can lead to reduced shelf-life and therapeutic efficacy. By employing a combination of specific excipients and precise pH control, the invention provides stable, ready-to-use liquid formulations of bisphosphonates.
What Are the Key Claims of U.S. Patent 9,539,241?
The claims of U.S. Patent 9,539,241 define the legal scope of protection. The patent contains multiple independent and dependent claims, detailing various aspects of the claimed compositions.
Independent Claim 1 is foundational, defining a pharmaceutical composition comprising:
- A bisphosphonate;
- An amino acid in an amount from 0.01% to 10% by weight;
- A chelating agent in an amount from 0.001% to 1% by weight; and
- An aqueous solvent;
wherein the composition has a pH of 3.5 to 7.0.
The bisphosphonates covered by the patent include, but are not limited to:
- Alendronate
- Risedronate
- Ibandronate
- Zoledronate
- Pamidronate
- Etidronate
The amino acids mentioned in the patent include:
- Glycine
- Alanine
- Lysine
- Glutamic acid
- Aspartic acid
Chelating agents identified include:
- EDTA (ethylenediaminetetraacetic acid)
- DTPA (diethylenetriaminepentaacetic acid)
- Citric acid
Dependent Claim 2 further refines Claim 1, specifying that the bisphosphonate is present in an amount from 0.01% to 5% by weight.
Dependent Claim 3 specifies that the amino acid is glycine.
Dependent Claim 4 specifies that the chelating agent is EDTA.
Dependent Claim 5 further restricts the pH range to between 4.0 and 6.0.
Dependent Claim 6 adds a buffering agent to the composition. Examples of buffering agents include citrate buffers and acetate buffers.
Dependent Claim 7 claims a pharmaceutical composition further comprising a tonicity agent, such as sodium chloride.
The claims collectively define a precise formulation for stable bisphosphonate solutions, emphasizing the synergistic effect of specific excipients and pH on drug stability. The protection extends to any composition that meets all the limitations of the claims.
What Is the Prior Art Landscape for Bisphosphonate Formulations?
The patent landscape for bisphosphonate formulations is characterized by significant innovation, driven by the need for improved drug delivery, stability, and patient compliance. Prior art reveals a long history of research into bisphosphonate stabilization and various dosage forms.
Key areas of prior art include:
- Oral Formulations: Early bisphosphonate patents primarily focused on oral dosage forms, addressing issues like poor bioavailability and gastrointestinal side effects. These often involved specific tablet coatings or co-formulations with absorption enhancers.
- Injectable Formulations: As the therapeutic utility of bisphosphonates expanded, the need for stable injectable formulations grew. This area has seen numerous patents addressing:
- Lyophilized Powders: Many bisphosphonates are formulated as lyophilized powders that are reconstituted before injection. Patents in this area focus on excipients that promote freeze-drying stability and rapid reconstitution.
- Liquid Injectables: The development of ready-to-use liquid injectable formulations has been a significant area of innovation. Prior art in this domain often grapples with the inherent instability of bisphosphonates in aqueous solutions. Patents have explored:
- pH Adjustment: Similar to U.S. Patent 9,539,241, many prior art formulations adjust pH to stabilize bisphosphonates. However, the specific ranges and combinations of excipients can vary.
- Antioxidants: Some formulations include antioxidants to prevent oxidative degradation.
- Complexing Agents: The use of chelating agents to sequester metal ions, which can catalyze degradation, is also a common theme in prior art.
- Specific Salt Forms: Patents may also cover specific salt forms of bisphosphonates that exhibit improved stability or solubility.
- Combination Therapies: Patents have also explored combining bisphosphonates with other therapeutic agents to enhance efficacy or address multifaceted bone disorders.
Key Competitors and Patent Holders: Major pharmaceutical companies with significant portfolios in bone disease treatments are active in this space. These include but are not limited to:
- Merck & Co.: Known for alendronate (Fosamax) and risedronate (Actonel, in collaboration with others).
- Amgen: Developed denosumab (Prolia), a biologic targeting bone resorption, and has intellectual property related to bone disease treatments.
- Sanofi: Has a history with bisphosphonates and osteoporosis treatments.
- Novartis: Developed zoledronic acid (Reclast, Zometa) and has extensive patent activity in the area.
- B. Braun Melsungen AG: The assignee of U.S. Patent 9,539,241, this company is focused on medical devices and pharmaceuticals, including intravenous solutions and drug delivery systems.
The prior art reveals that while the concept of stabilizing bisphosphonates is not new, the specific combination of excipients and pH parameters claimed in U.S. Patent 9,539,241 represents a distinct inventive step, likely overcoming specific stability challenges not fully addressed by earlier formulations. The patent's value lies in its ability to define a stable, commercially viable liquid formulation.
What Is the Market Relevance and Commercial Potential of U.S. Patent 9,539,241?
The market relevance of U.S. Patent 9,539,241 is directly tied to the significant and growing market for osteoporosis and other bone disease treatments. Bisphosphonates remain a cornerstone therapy for these conditions, and stable, convenient liquid formulations are highly desirable for both healthcare providers and patients.
Market Size and Trends:
- The global osteoporosis drug market was valued at approximately $10.7 billion in 2022 and is projected to reach $15.3 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.6% [1].
- The increasing elderly population worldwide is a primary driver for the growth of this market, as osteoporosis incidence rises with age.
- There is a growing demand for patient-friendly drug delivery systems. Stable, ready-to-use liquid formulations can improve adherence compared to older oral formulations with complex dosing regimens and dietary restrictions.
Commercial Potential of the Patented Technology:
- Improved Patient Compliance: A stable, liquid formulation bypasses the need for reconstitution, which can be a barrier for some patients. It also offers a potentially more convenient administration route than daily or weekly oral pills for certain patient populations.
- Extended Shelf-Life: The stability addressed by the patent directly translates to a longer shelf-life for the product, reducing waste and improving logistical efficiency for manufacturers and distributors.
- Therapeutic Advantage: By ensuring consistent drug potency, the patented formulation can deliver reliable therapeutic outcomes, reinforcing its value proposition.
- Potential for New Product Launches: For B. Braun Melsungen AG or any licensee, this patent offers a pathway to develop and market new bisphosphonate products with distinct advantages over existing therapies, particularly in the injectable segment.
- Licensing Opportunities: The patent can be a valuable asset for licensing to other pharmaceutical companies looking to enter or expand their presence in the bisphosphonate market with a stable liquid formulation.
Competitive Landscape and Infringement Risk:
The patent protects specific compositions. Companies developing or marketing bisphosphonate injectable formulations must carefully navigate this patent. Infringement would occur if a competitor's product contains a bisphosphonate, an amino acid, a chelating agent, and an aqueous solvent, all within the specified concentration and pH ranges defined by the patent claims.
While newer biologics and different drug classes are emerging for osteoporosis, bisphosphonates remain a cost-effective and widely utilized treatment. Stable liquid formulations are a key area of differentiation and commercial success in this established market. The patent provides a competitive edge by protecting a specific, innovative approach to achieving such formulations.
How Does U.S. Patent 9,539,241 Relate to Existing Bisphosphonate Drugs?
U.S. Patent 9,539,241 does not claim new bisphosphonate active pharmaceutical ingredients (APIs). Instead, it claims novel pharmaceutical compositions that utilize existing, well-established bisphosphonate drugs. This means the patent focuses on the formulation of these drugs rather than the discovery of new chemical entities.
The patent is relevant to a range of bisphosphonate drugs that are currently marketed or have been developed for treating bone disorders. These include, but are not limited to:
- Alendronate: Widely prescribed for osteoporosis and Paget's disease. Available in oral tablet form and previously in once-weekly oral solutions.
- Risedronate: Used for osteoporosis, Paget's disease, and glucocorticoid-induced osteoporosis. Available in oral tablets and capsules.
- Ibandronate: Used for osteoporosis. Available in oral tablets and intravenous injection.
- Zoledronic Acid: Used for osteoporosis and hypercalcemia of malignancy. Available as an intravenous infusion.
- Pamidronate: Used for hypercalcemia of malignancy, Paget's disease, and bone metastases. Available as an intravenous infusion.
The invention described in U.S. Patent 9,539,241 aims to provide stable liquid formulations for these bisphosphonates. This is particularly significant for drugs that are currently available primarily in oral forms or as lyophilized powders requiring reconstitution for injection.
Key relationships include:
- Improved Delivery of Existing Drugs: The patent enables the development of improved dosage forms for existing bisphosphonates. For example, if a company holds rights to alendronate but struggles with the stability of a liquid formulation, this patent provides a potential solution.
- Addressing Formulation Challenges: Many bisphosphonates, when formulated in aqueous solutions, can degrade, precipitate, or form aggregates. This patent offers a specific chemical approach (stabilizers and pH control) to overcome these common formulation challenges, thereby extending the therapeutic utility and commercial viability of these established drugs.
- Market Differentiation: By securing a patent on a superior formulation, a company can differentiate its product from generic or less stable versions of the same API. This is crucial in the pharmaceutical market where patent protection for new formulations can extend market exclusivity.
- Potential for New Indications or Patient Groups: A more stable and convenient formulation might allow for exploration of new administration routes, dosing frequencies, or suitability for patient populations that were previously underserved due to formulation limitations.
- Freedom to Operate and Potential for Litigation: Companies that manufacture or plan to manufacture bisphosphonate liquid formulations must assess whether their products fall within the scope of this patent's claims. This patent represents a potential barrier to entry or a basis for licensing agreements. Conversely, the patent holder can assert their rights against infringing products.
In essence, U.S. Patent 9,539,241 acts as a protective layer for the specific way bisphosphonates are formulated into stable liquid pharmaceutical compositions. It allows for the enhanced presentation and delivery of established bisphosphonate molecules.
Key Takeaways
- U.S. Patent 9,539,241 protects novel pharmaceutical compositions containing bisphosphonates, focusing on enhancing drug stability in aqueous solutions.
- The core innovation lies in the specific combination of bisphosphonate APIs with amino acids, chelating agents, and precise pH control (3.5-7.0) within an aqueous solvent.
- Key claims define specific types and concentrations of excipients, including glycine, alanine, lysine, and EDTA, as well as pH ranges like 4.0-6.0.
- The prior art landscape is active, with significant patenting activity in oral and injectable bisphosphonate formulations, but the claimed combination represents a distinct stabilization approach.
- The commercial relevance is substantial, driven by the large and growing market for osteoporosis treatments and the demand for convenient, stable liquid drug formulations.
- The patent is relevant to existing bisphosphonate drugs, offering improved delivery and market differentiation through enhanced formulation stability.
Frequently Asked Questions
-
Does U.S. Patent 9,539,241 cover the bisphosphonate drugs themselves?
No, the patent covers novel pharmaceutical compositions containing bisphosphonates, not the bisphosphonate active pharmaceutical ingredients (APIs) themselves, which are likely covered by separate composition of matter patents or are off-patent.
-
What are the specific bisphosphonates that can be formulated using this patent?
The patent claims are broad enough to cover various bisphosphonates including alendronate, risedronate, ibandronate, zoledronate, pamidronate, and etidronate, among others.
-
What is the primary benefit of the compositions claimed in this patent?
The primary benefit is enhanced stability of bisphosphonates in aqueous solutions, which can lead to improved shelf-life, consistent potency, and potentially more convenient liquid dosage forms.
-
Can a company legally develop a bisphosphonate liquid formulation without considering this patent?
Companies developing bisphosphonate liquid formulations must conduct a freedom-to-operate analysis to determine if their specific composition falls within the scope of U.S. Patent 9,539,241's claims, as infringement could lead to legal action.
-
What role do amino acids and chelating agents play in the claimed compositions?
Amino acids act as stabilizers and can contribute to buffering, while chelating agents like EDTA bind metal ions that can catalyze bisphosphonate degradation, collectively improving the overall stability of the formulation.
Citations
[1] Global osteoporosis drugs market size value to reach USD 15.3 billion by 2030, growing at 4.6% CAGR. (2023, May 30). Precedence Research. Retrieved from https://www.precedenceresearch.com/osteoporosis-drugs-market
